Intraperitoneal injection of 500 μg/kg irisin daily for 8 weeks increased the number and improved the function of EPCs in diabetes mellitus mice by influencing the PI3K/Akt/eNOS pathway, indicating irisin as a potential interventional therapy to improve EPC function for diabetic patients [12]. This evidence concerns the gene AKT1 and diabetes mellitus.